These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28536307)

  • 1. Gene Expression Profiling in
    Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
    Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
    Lewis KD; Larkin J; Ribas A; Flaherty KT; McArthur GA; Ascierto PA; Dréno B; Yan Y; Wongchenko M; McKenna E; Zhu Q; Mun Y; Hauschild A
    Br J Cancer; 2019 Oct; 121(7):522-528. PubMed ID: 31417188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
    Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
    Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
    Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
    Wongchenko MJ; Ribas A; Dréno B; Ascierto PA; McArthur GA; Gallo JD; Rooney IA; Hsu J; Koeppen H; Yan Y; Larkin J
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):516-522. PubMed ID: 29156488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF
    Robert C; Lewis KD; Gutzmer R; Stroyakovskiy D; Gogas H; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Caro I; Forbes H; Shah K; Yan Y; Li H; McArthur GA; Ascierto PA
    Ann Oncol; 2022 May; 33(5):544-555. PubMed ID: 35131452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T; Nouri N; Garbe C
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
    Ascierto PA; Ribas A; Larkin J; McArthur GA; Lewis KD; Hauschild A; Flaherty KT; McKenna E; Zhu Q; Mun Y; Dréno B
    J Transl Med; 2020 Aug; 18(1):294. PubMed ID: 32746839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
    de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
    J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cobimetinib.
    Signorelli J; Shah Gandhi A
    Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
    Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
    Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
    Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
    Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cobimetinib and vemurafenib for the treatment of melanoma.
    Boespflug A; Thomas L
    Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
    Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.